Drug profile · INN
burosumab
CRYSVITA
burosumab (CRYSVITA) is a fibroblast growth factor 23 inhibitor. Associated with KYOWA KIRIN AUSTRALIA PTY LTD.
EMA: approved TGA: approved PMDA: approved Musculo-skeletal system (M05) M05BX05
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — burosumab
- Class
- Musculo-skeletal system (M05)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
burosumab (CRYSVITA) is a fibroblast growth factor 23 inhibitor. Associated with KYOWA KIRIN AUSTRALIA PTY LTD.
Key facts
INN burosumab
Brand CRYSVITA
Mechanism Fibroblast growth factor 23 inhibitor
Target Fibroblast growth factor 23
Therapeutic class Musculo-skeletal system (M05)
ATC code M05BX05
Originator KYOWA KIRIN AUSTRALIA PTY LTD
Mechanism of action
Fibroblast growth factor 23 inhibitor
Primary target: Fibroblast growth factor 23
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is burosumab?
burosumab (CRYSVITA) is a fibroblast growth factor 23 inhibitor. Associated with KYOWA KIRIN AUSTRALIA PTY LTD.
What is the brand name for burosumab?
CRYSVITA is a marketed brand name for burosumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.